Compare Global Payments Inc (GPN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Mesoblast Limited — how do they compare? Global Payments Inc trades at $82.2 (market cap $21.46B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Global Payments Inc is far larger — about 12.3× Mesoblast Limited's market cap, and Global Payments Inc pays a 1.23% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Mesoblast Limited for 15 Days on average.
| GPN | MESO | |
|---|---|---|
Market Cap | $21.46B | $1.75B |
Volume | 1,482,600 | 239,027 |
Sector | Financials | Health |
52-Week High | $94.83 | $20.96 |
52-Week Low | $62.47 | $13.19 |
Typical Hold Time | 50 Days | 15 Days |
Enterprise Value | $39.60B | $1.83B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.20, up 1.38% with neutral technical signals. The stock shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net margins. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains bullish with a $102.75 price target.
Investment outlook balances growth catalysts from digital payment expansion against rising costs and competitive pressures. The 24% upside to consensus target offers potential reward, but investors must weigh debt levels increasing to 41.57% debt-to-asset ratio and projected 2026 net loss against strategic initiatives. Near-term performance hinges on Q3 earnings delivery and Genius adoption metrics.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
